A Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa
Phase of Trial: Phase III
Latest Information Update: 23 May 2017
At a glance
- Drugs Rasagiline (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Takeda
- 27 Mar 2017 Status changed from active, no longer recruiting to completed.
- 28 Sep 2016 Planned number of patients changed from 182 to 200.
- 28 Sep 2016 Planned End Date changed from 1 May 2017 to 1 Mar 2017.